Preclinical Evaluation of Carfilzomib for Infant KMT2A-Rearranged Acute Lymphoblastic Leukemia

Cancer Therapy: Preclinical Effective Targeting of the P53–MDM2 Axis in Preclinical Models of Infant MLL-Rearranged Acute Lymphoblastic Leukemia

Purpose: Although the overall cure rate for pediatric acute lymphoblastic leukemia (ALL) approaches 90%, infants with ALL harboring translocations in the mixed-lineage leukemia (MLL) oncogene (infant MLL-ALL) experience shorter remission duration and lower survival rates ( 50%). Mutations in the p53 tumor-suppressor gene are uncommon in infant MLL-ALL, and drugs that release p53 from inhibitory...

Infant Acute Lymphoblastic Leukemia

Acute lymphoblastic leukemia (ALL) in infants under 12 months of age accounts for about 4% of childhood ALL and differs from ALL in older children with respect to immunophenotypic, cytogenetic and molecular genetic features. In contrast to the predominance of male sex in older children with ALL, there is a slight predominance of girls in infant ALL (1). In infant leukemia, all necessary genetic...

Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia.

PURPOSE Although the overall cure rate for pediatric acute lymphoblastic leukemia (ALL) approaches 90%, infants with ALL harboring translocations in the mixed-lineage leukemia (MLL) oncogene (infant MLL-ALL) experience shorter remission duration and lower survival rates (∼50%). Mutations in the p53 tumor-suppressor gene are uncommon in infant MLL-ALL, and drugs that release p53 from inhibitory ...

Simultaneous Neuroblastoma and Acute Lymphoblastic Leukemia in an Infant

Prognostic significance of high-level FLT3 expression in MLL-rearranged infant acute lymphoblastic leukemia.

2007;39:86-92. 3. Person RE, Li FQ, Duan Z, et al. Mutations in proto-oncogene GFI1 cause human neutropenia and target ELA2. Nat Genet. 2003;34:308-312. 4. Donini M, Fontana S, Savoldi G, et al. G-CSF treatment of severe congenital neutropenia reverses neutropenia but does not correct the underlying functional deficiency of the neutrophil in defending against microorganisms. Blood. 2007;109:471...